tbuckley/cabot-search huggingface dataset:
Evaluation of invasive breast cancer using a 12-chemokine gene expression score (CS): Correlation with clinical outcomes.
Authors: Sangeetha Prabhakaran, Victoria T. Rizk, William J. Fulp, Anders E. Berglund, James J Mule', Hatem Hussein Soliman
Journal: Journal of Clinical Oncology (2015)

11050 Background: We derived a unique CS from a metagene grouping with high enrichment for immune-and inflammation-related genes that in various tumors including breast cancer, accurately predicts the degree and type of lymphoid infiltrate close to tumor aggregates and areas of tumor necrosis and shows improved overall survival (OS) in Stage IV melanoma. (Messina JL et. al Scientific Reports 2012). We analyzed the correlation between the CS, clinicopathologic variables and survival in breast cancer patients (pts). Methods: A retrospective review was performed on selected Stage I - III breast cancer pts treated at our institution from 1978 to 2011. CS were calculated by principal component analysis. Pts given neoadjuvant chemotherapy were excluded. Pts were divided into 2 groups at the median into high or low CS. Descriptive and survival analyses were performed. Results: 366 pts were included, median age at diagnosis was 54.5 years. Pts mainly presented with Stage II disease (51.8 %) with ductal histology (77.6 %) and were ER/PR positive (63.5%). 86.5% received adjuvant therapy after surgery. Mean CS was 0.23 (range -2.2 to 2.1). Median follow-up period was 66.3 months (mths) (range 2.5 - 212.9). 263 pts were alive and 82.5% disease free at analysis. 88 (37 vs. 51) pts recurred in high vs. low CS groups. In comparison with the low CS group, patients with high CS were more likely to be white (172 vs. 159) (P = 0.03), with poorly differentiated tumors (112 vs. 59) (P < .0001), ER/PR negative (41 vs. 26) and Her2 positive (36 vs. 19) (P = 0.001). They had better OS (median 17.5 vs. 13) (P = 0.88) and recurrence free survival (RFS) (median not reached vs.11.1) mths (P = 0.128) compared to low CS. Higher scores in Her2 positive pts correlated with increased RFS (12.4 vs. 4.4 mths) that trended towards significance (P = 0.058). Conclusions: Higher scores are associated with high grade tumors and aggressive subtypes. They also correlate with improved OS and RFS. Further studies using larger datasets to repeat these observations and select tumor subtypes could extend the predictive value of this novel CS and potentially identify candidates for immunotherapeutic treatment.
The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis
Authors: O. Osinubi, M.J. Grainge, L. Hong, A. Ahmed, J.M. Batchelor, D. Grindlay, A.R. Thompson, S. Ratib
Journal: British Journal of Dermatology (2017)

Vitiligo is a chronic disorder causing skin depigmentation with global prevalence varying from 0·2% to 1·8%. U.K. guidelines recommend assessment of psychological state during clinical evaluation of vitiligo. However, the prevalence of psychological comorbidity in people with vitiligo has not been described.To establish the prevalence of psychological symptoms or disorders in people with vitiligo and describe the outcome measures used.We performed a comprehensive search of MEDLINE, Embase, CINAHL and PsycINFO to identify observational studies assessing the prevalence of psychological symptoms or disorders (December 2016). DerSimonian and Lard random-effects models were used to estimate the overall pooled prevalence.We identified 29 studies with 2530 people with vitiligo. Most studies included a measure of either depression (n = 25) or anxiety (n = 13). The commonest tools were the Hospital Anxiety and Depression Scale and the Centre for Epidemiology Studies Depression Scale. Ten studies provided information on 13 other psychological outcomes. Pooled prevalence using depression-specific and anxiety-specific questionnaires was 0·29 [95% confidence interval (CI) 0·21-0·38] and 0·33 (95% CI 0·18-0·49), respectively. Prevalence was lower for clinically diagnosed depression (0·21, 95% CI 0·15-0·28) and anxiety (0·15, 95% CI 0·06-0·24). When nonspecific tools were used the prevalence remained similar for depression (0·27, 95% CI 0·08-0·46) but increased for anxiety (0·46, 95% CI 0·39-0·52). High heterogeneity was observed.A range of psychological outcomes are common in people with vitiligo. The prevalence of anxiety was influenced by type of screening tool, suggesting the need for validation of psychological outcome screening tools in the field of dermatology.
Epidémie de rougeole chez des enfants de moins de 15 mois à La Rioja, Espagne, 2005-2006
Authors: M Perucha, E Ramalle-Gómara, M E Lezaun, A Blanco, C Quiñones, M Blasco, M A Gonzalez, C Cuesta, J E Echevarria, M M Mosquera, F de Ory
Journal: Eurosurveillance (2006)

Cet article decrit une epidemie de rougeole qui a debute a La Rioja, Espagne, en decembre 2005. Cette epidemie a essentiellement touche des enfants de moins de 15 mois qui n’avaient pas encore ete vaccines avec le vaccin du ROR. Les cas de rougeole ont ete detectes par le systeme de declaration obligatoire, auquel les laboratoires doivent rapporter tous les cas confirmes de rougeole. La classification en cas suspects ou cas confirmes est en accord avec le plan national d’elimination de la rougeole. Entre le 14 decembre 2005 et le 19 fevrier 2006, 29 cas suspects de rougeole ont ete investigues, et 18 ont ete confirmes. La periode d’incubation moyenne etait de 13,8 jours (de 9 a 18). Sur les 18 cas confirmes, seuls deux etaient des adultes. La vaccination ROR a ete recommandee pour tous les contacts d’un meme foyer, ainsi que pour les enfants de 6 a 14 mois qui frequentaient les centres de soins ou etaient apparus les cas. Dans ces etablissements, la deuxieme dose de vaccin ROR a ete administree aux enfants de moins de trois ans, soit plus tot que prevu dans le calendrier. L’administration de la premiere dose de vaccin ROR a egalement ete recommandee pour tous les enfants entre 9 et 14 mois. Lors d’une epidemie de rougeole, une premiere dose de vaccin devrait etre administree le plus vite possible a tous les enfants de six mois ou plus non encore vaccines avec ce vaccin. De meme, une deuxieme dose devrait etre administree le plus rapidement possible a tous ceux qui ont deja recu la premiere dose, tout en respectant le delai de 1 mois entre les deux doses.
Delirium in Hospitalized Older Adults
Authors: Edward R. Marcantonio
Journal: New England Journal of Medicine (2017)

A 75-year-old man is admitted for scheduled major abdominal surgery. He is functionally independent, with mild forgetfulness. His intraoperative course is uneventful, but on postoperative day 2, severe confusion and agitation develop. What is going on? How would you manage this patient’s care? Could his condition have been prevented?
Abstract 360: Implantation of an Induced Pluripotent Stem Cell Derived Cardiomyocyte Tissue Engineered Patch Improves Left Ventricular Function and Electro-mechanical Coupling in Rats With Heart Failure
Authors: Jordan J Lancaster, Giuliana Repetti, Amitabh Pandey, Kyle Weigand, Joseph J Bahl, Elizabeth Juneman, Steven Goldman
Journal: Circulation Research (2016)

Background: Chronic Heart Failure (CHF) is the leading cause of hospital readmissions and mortality in the US. Here we report the effects of surgically delivering a human bioengineered patch of human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CMs) and fibroblasts on left ventricular (LV) function in rats with CHF. We evaluate improvements in LV systolic and diastolic function, electromechanical coupling and gene expression after patch implantation. Methods: Adult male Sprague-Dawley rats underwent left coronary artery ligation and were randomized to Sham (N=8), CHF (N=8-21), and CHF+hiPSC-CM patch (N=20-24). Heterogeneous hiPSC-CMs were seeded and co-cultured onto a vicryl matrix embedded with human dermal fibroblasts. Echocardiography was performed at 3 and 6 weeks post-randomization. Hemodynamic pressure measurements were performed at 6 weeks post-ligation with Millar solid state micromanometer pressure catheters. Open chest Electrophysiologic (EP) mapping was performed at 6 weeks post ligation. Gene expression was evaluated through qRT-PCR. Results: 48 hours into culture hiPSC-CMs patches displayed synchronized and spontaneous contractions which developed in robustness over time. At maximal robustness, contractions were visualized across the full thickness of the construct. Contractions were recorded at 36 + 5 beats BPM. Three weeks after patch implantation (6 weeks post ligation) the hiPSC-CM patch decreased (P&lt;0.05) LV EDP (45%), Tau (29%), E/e’ (23%) and increased (P&lt;0.05), e’/a’ (36%) with trending improvements in EF (14%) and e’ (20%). EP studies show electro-mechanical coupling between the patch and the native myocardium with normal activation through the patch and increases (P&lt;0.05) voltage amplitude in CHF versus hiPSC-CM patch treated rats (1±0.5 mV vs 6±1.5mV). Rats treated with the hiPSC-CM patch showed significant (P&lt;0.05) fold expression of Cx43 (3.3), ANG-1 (13.63), VEGF (3.8), βMYH7 (6.4) and IGF-1 (22.9) versus control. Conclusion: Cardiac patch implantation with hiPSC derived cardiomyocytes is an effective and feasible method of treating CHF with improvements in systolic function, diastolic function, and electro-mechanical coupling in rats with CHF.
GW28-e0977 A study on the mechanism of the inflammatory response in Ginsenoside Rb1 against the intrinsic aging of mouse brain
Authors: Bin Zhou, Shujie Yu, Dinghui Liu, Min Wang, Lin Wu, Yong Liu, Xianguan Yu, Yesheng Ling, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2017)
Increase in invasive group A streptococcal infections in England, Wales and Northern Ireland, 2008-9
Authors: T  L Lamagni, A Efstratiou, J Dennis, P Nair, J Kearney, R George, Collective on behalf of the national incident management team
Journal: Eurosurveillance (2009)

Increases in invasive and non-invasive group A streptococcal diseases are currently being seen in the United Kingdom. National enhanced surveillance is being launched to examine the clinical presentations, risk factors, outcome and clustering patterns of cases to further inform public health management strategies.
CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial”
Authors: Y. Brandberg, S. Loibl, T. Foukakis, H. Johansson, M. Gnant, C.F. Singer, G. von Minckwitz, N.-O. Bengtsson, E. Karlsson, B. Mlineritsch, M. Hellström, G. Steger, L. Carlsson, D. Egle, R. Greil, J. Bergh
Journal: Annals of Oncology (2017)
Factors associated with reduced work ability in a nation-wide cohort of long-term cancer survivors treated in young adulthood (19-39 years): The NOR-CAYACS study
Authors: C.E. Kiserud, H.C. Lie, A. Finset, S. Fosså, J.H. Loge, E. Ruud, A.A. Dahl
Journal: Annals of Oncology (2017)
Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC)
Authors: F. Rivera Herrero, J-B. Bachet, D.P. Modest, F. de Braud, F. Pietrantonio, R. Koukakis, G. Demonty, J-Y. Douillard
Journal: Annals of Oncology (2017)
ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)
Authors: B. Tombal, F. Saad, M. Hussain, C.N. Sternberg, K. Fizazi, E.D. Crawford, K. Yamada, C. Kappeler, I. Kuss, M.R. Smith
Journal: Annals of Oncology (2017)
Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)
Authors: A.B. Schrock, D. Fabrizio, Y. He, J. Chung, M. Resnick, P.J. Stephens, J.S. Ross, V.A. Miller, S. Ramkissoon, J.A. Elvin, S.M. Ali, M. Fakih, S.J. Klempner
Journal: Annals of Oncology (2017)
Transcriptional control of IDO by the cancer suppression gene Bin1, a key mechanism for restraining tumor immune escape
Authors: Alexander J. Muller, James B. Duhadaway, Erika Sutanto-Ward, P. Scott Donover, George C. Prendergast
Journal: Cancer Research (2005)

5307   Immune escape is a central hallmark of cancer. It has long been recognized that tumor cells escape immune destruction by defeating immune surveillance and do so despite displaying recognizable tumor antigens. This phenomenon is central to tumor cell survival and suggests that defeating immune escape could have wide therapeutic benefit. However, the underlying genetic basis for immune escape by tumors is poorly understood. We have determined that  Bin1  loss can promote tumor formation by facilitating escape from host anti-tumor immunity. Homozygous deletion of the  Bin1  gene greatly enhances tumor formation by  Myc+Ras- transformed murine skin keratinocyte (MR KEC) isografts in syngeneic hosts but not in athymic nude mice or in syngeneic mice immunodepleted of T cells. These data suggest a cell-extrinsic effect on anti-tumor immunity. A candidate mediator of this effect, indoleamine 2,3-dioxygenase (IDO), is being investigated. Catabolism of tryptophan by IDO can block T cell activation and promote immune tolerance.  Bin1 -/- cells exhibit superinducible IDO, suggesting a mechanism that might account for the more aggressive growth of  Bin1 -/- isografts in immunocompetent hosts. Supporting this idea, treatment of Bin1-null MR KEC tumors with a bioavailable inhibitor of IDO suppresses their outgrowth in immunocompetant mice but has no impact on growth of these tumors in T cell deficient animals. We have investigated further how  Bin1  attenuation elevates expression of the IDO gene. In transient promoter-reporter assays conducted in HeLa cells with a 900 bp fragment of the mouse  IDO  promoter, we show that inhibiting  Bin1  by either siRNA or dominant negative strategies increases both basal and IFN-γ-induced  IDO  promoter activity. Activation of the  IDO  promoter by IFN-γ is known to be dependent on the transcription factors STAT1 and NF-κB. Based on evidence that intracellular trafficking of both STAT1 and NF-κB may be modulated by Bin1/Amphiphysin, we have examined roles for them in Bin1 - dependent regulation of  IDO  in MR KECs. Consistent with the results in HeLa cells,  Bin1  deletion compromises both basal and IFN-γ-induced transcription from the  IDO  promoter in MR KECs, and this effect is reversed in  Bin1  addback experiments. Introduction of a “super-repressor” mutant of IκB, which can prevent NF-κB activation by upstream stimuli, abolishes the benefits of  Bin1  deletion to  IDO  transcription. Similarly, introduction of a dominant negative mutant STAT1 Y701F, which limits STAT-mediated activation, abolishes the benefit of  Bin1  deletion to  IDO  transcription. Taken together, these results indicate that the genetic control  Bin1  exerts over  IDO  expression is mediated through NF-κB-dependent and STAT-dependent transcription.
Clinical dysregulation of DNA repair by the polynucleotide kinase/phosphatase-XRCC4-DNA ligase IV in neurological disease
Authors: D. Aceytuno, C.G. Piett, Z. Havali-Shahriari, R.A. Edwards, M. Rey, R.S. Mani, S. Fang, M. Hammel, M. Weinfeld, J.A. Tainer, D. Schriemer, S.P. Lees-Miller, J.N.M. Glover
Journal: Annals of Oncology (2017)
Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): Time to maximum response and optimal treatment duration
Authors: A. Lamarca, J. Barriuso, L. McCallum, G. Papaxoinis, M. Nasralla, C. Nuttall, M. Frizziero, Z. Kordatou, M.G. McNamara, R.A. Hubner, P. Manoharan, W. Mansoor, J.W. Valle
Journal: Annals of Oncology (2017)
Early response evaluation by 18F-FDG-PET influences management in gastrointestinal stromal tumor patients treated with neo-adjuvant intent
Authors: S. Farag, L-F. de Geus-Oei, W.T.A. van der Graaf, F. Van Coevorden, D.J. Grunhagen, A. Reyners, P. Boonstra, I. Desar, H. Gelderblom, N. Steeghs
Journal: Annals of Oncology (2017)
Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somatic PIK3CA or KRAS mutations
Authors: A. Ogasawara, T. Hihara, A. Yabuno, S. Shimoyokkaichi, D. Shintani, Y. Ikeda, K. Tai, K. Fujiwara, K. Watanabe, K. Hasegawa
Journal: Annals of Oncology (2017)
Dose escalation study of vemurafenib with crizotinib or sorafenib in patient with BRAF-mutated advance cancers
Authors: D. Sakamuri, S. Kato, H.J. Huang, A. Naing, V.R. Holley, S. Patel, S.A. Piha-Paul, A.M. Tsimberidou, D.S. Hong, F. Meric-Bernstam, F. Janku
Journal: Annals of Oncology (2017)
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC)
Authors: A-K.A. Lalani, W. Xie, D.J. Martini, C.K. Norton, J.A. Steinharter, D. Bossé, J. Bellmunt, E.M. Van Allen, B.A. McGregor, L.C. Harshman, T.K. Choueiri
Journal: Annals of Oncology (2017)
The WHO European report confirms links between socioeconomic development and health
Journal: Eurosurveillance (2002)

Over 300 representatives, including 20 ministers of health, attended the 52nd session of the World Health Organisation (WHO) Regional Committee for Europe, which was held from 16 to 19 September in Copenhagen, Denmark. On this occasion the European Health Report 2002 was released. This report confirms the strong links between socioeconomic development, health and equity in the WHO European Region which covers 51 WHO Member States with some 870 million people. While overall levels of health in the Region are among the highest in the world, the report describes widening gaps between and within countries (www.euro.who.int/europeanhealthreport).
Gemcitabine and platinum- based chemotherapy in first line treatment of hepatocholangiocarcinoma: An AGEO multicenter retrospective study
Authors: M. Salimon, C. Prieux-Klotz, D. Tougeron, T. Lecomte, M. Caulet, T. Matysiak Budnik, V. Hautefeuille, M. Tiako-Meyo, A. Zaanan, Y. Touchefeu
Journal: Annals of Oncology (2017)

Background: Hepatocholangiocarcinoma (cHCC-ICC) is a rare primary hepatic tumor combining features of cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC). The aim was to evaluate the overall survival (OS), progression free survival (PFS) and prognostic factors in unresectable cHCC-ICC treated by gemcitabine (gem) and platinum- based chemotherapy in first line systemic treatment. Methods: Data from patients treated for advanced cHCC-ICC by gem and platinum- based chemotherapy in six French university hospitals between 2008 and 2016, were retrospectively collected. The diagnosis of cHCC-ICC was based on histological analysis or, in case of typical histology of ICC or HCC, on discordant CT-Scan findings and/or tumor marker (alpha-fetoprotein, carbohydrate antigen 19-9, carcinoembryonic antigen) serum levels suggesting the alternative histology. OS and PFS were estimated by Kaplan-Meier method. Prognostic factors were analyzed by Log-rank test in univariate analysis and by Cox model in multivariate analysis. Statistical analysis was performed using Graph Pad Prism 6. Results: Forty patients were included (70% men, median age 66 years [extremes 32-88]). cHCC-ICC was histologically proven in 55% of cases. At diagnosis, twenty-three patients (57.5%) had metastatic synchronous lesion. Twenty-nine patients (72.5%) were treated by gem + oxaliplatine (GEMOX), 9(22.5%) by GEMOX + bevacizumab, 2(5%) by gem + cisplatine. Eighteen patients (45%) received second line of treatment. In the first line, patients received a median of 10 cycles of chemotherapy (extremes 1-28). RECIST1.1 criteria were reported in 35 cases: 9 patients (25.7%) had partial response, 18 (51.4%) had stable disease, 8 (22.8%) had tumor progression at first evaluation. Median PFS and OS were 9 and 15.4 months, respectively. In multivariate analysis, significant prognostic factors of poor OS were: positive serology for hepatitis B virus and/or C (HR = 1.35 IC95% [1.13-13.24] p = 0.031), serum bilirubin level > 30µmol/L (HR = 1.66 IC95% [1.57-17.54] p = 0.007), ECOG score ≥ 2 (HR = 2.46 IC95% [2.23-61.75] p = 0.004). Conclusions: These data suggest a chemosensitivity of cHCC-ICC to gemcitabine and platinum based chemotherapy. Legal entity responsible for the study: Dr. Yann Touchefeu Funding: None Disclosure: All authors have declared no conflicts of interest.
Loss of CLOCK Results in Dysfunction of Brain Circuits Underlying Focal Epilepsy
Authors: Peijun Li, Xiaoqin Fu, Nathan A. Smith, Julie Ziobro, Julian Curiel, Milagros J. Tenga, Brandon Martin, Samuel Freedman, Christian A. Cea-Del Rio, Livio Oboti, Tammy N. Tsuchida, Chima Oluigbo, Amanda Yaun, Suresh N. Magge, Brent O’Neill, Amy Kao, Tesfaye G. Zelleke, Dewi T. Depositario-Cabacar, Svetlana Ghimbovschi, Susan Knoblach, Chen-Ying Ho, Joshua G. Corbin, Howard P. Goodkin, Stefano Vicini, Molly M. Huntsman, William D. Gaillard, Gregorio Valdez, Judy S. Liu
Journal: Neuron (2017)
GW28-e0886 Apolipoprotein E-containing high-density lipoprotein (HDL) cholesterol is a better indicator for anti-atherosclerotic function of HDL than total HDL cholesterol: a community-based cohort study
Authors: Yue Qi, Jing Liu, Wei Wang, Miao Wang, Jiayi Sun, Jun Liu, Dong Zhao
Journal: Journal of the American College of Cardiology (2017)
Improving visualization and adherence by converting the Dutch colorectal cancer guidelines into decision trees: The Oncoguide project
Authors: M.G. van Oijen, X.A. Verbeek, T. van Vegchel, I.D. Nagtegaal, M.J. Lahaye, A. Méndez Romero, H. Rütten, S. de Bruijn, H.M. Verheul, P.J. Tanis, C.J.A. Punt, L. Keikes
Journal: Annals of Oncology (2017)
Environmental Suitability of <i>Vibrio</i> Infections in a Warming Climate: An Early Warning System
Authors: Jan C. Semenza, Joaquin Trinanes, Wolfgang Lohr, Bertrand Sudre, Margareta Löfdahl, Jaime Martinez-Urtaza, Gordon L. Nichols, Joacim Rocklöv
Journal: Environmental Health Perspectives (2017)

Some Vibrio spp. are pathogenic and ubiquitous in marine waters with low to moderate salinity and thrive with elevated sea surface temperature (SST).Our objective was to monitor and project the suitability of marine conditions for Vibrio infections under climate change scenarios.The European Centre for Disease Prevention and Control (ECDC) developed a platform (the ECDC Vibrio Map Viewer) to monitor the environmental suitability of coastal waters for Vibrio spp. using remotely sensed SST and salinity. A case-crossover study of Swedish cases was conducted to ascertain the relationship between SST and Vibrio infection through a conditional logistic regression. Climate change projections for Vibrio infections were developed for Representative Concentration Pathway (RCP) 4.5 and RCP 8.5.The ECDC Vibrio Map Viewer detected environmentally suitable areas for Vibrio spp. in the Baltic Sea in July 2014 that were accompanied by a spike in cases and one death in Sweden. The estimated exposure-response relationship for Vibrio infections at a threshold of 16°C revealed a relative risk (RR)=1.14 (95% CI: 1.02, 1.27; p=0.024) for a lag of 2 wk; the estimated risk increased successively beyond this SST threshold. Climate change projections for SST under the RCP 4.5 and RCP 8.5 scenarios indicate a marked upward trend during the summer months and an increase in the relative risk of these infections in the coming decades.This platform can serve as an early warning system as the risk of further Vibrio infections increases in the 21st century due to climate change. https://doi.org/10.1289/EHP2198.